Analyzing Palisade Bio (PALI) and The Competition

Palisade Bio (NASDAQ:PALIGet Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Palisade Bio to similar companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, risk and profitability.

Institutional and Insider Ownership

7.9% of Palisade Bio shares are owned by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 25.4% of Palisade Bio shares are owned by company insiders. Comparatively, 16.8% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Palisade Bio and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Palisade Bio $10,000.00 -$26.62 million -0.16
Palisade Bio Competitors $773.46 million $147.16 million -0.23

Palisade Bio’s rivals have higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for Palisade Bio and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio 0 0 2 0 3.00
Palisade Bio Competitors 1657 5735 11373 210 2.53

Palisade Bio currently has a consensus target price of $6.00, suggesting a potential upside of 1,053.85%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.99%. Given Palisade Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than its rivals.

Profitability

This table compares Palisade Bio and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Palisade Bio N/A -2,145.95% -273.04%
Palisade Bio Competitors -4,587.78% -67.40% -30.70%

Volatility & Risk

Palisade Bio has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Palisade Bio’s rivals have a beta of 0.76, meaning that their average stock price is 24% less volatile than the S&P 500.

Summary

Palisade Bio beats its rivals on 7 of the 13 factors compared.

Palisade Bio Company Profile (Get Rating)

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.